GO:0005681 spliceosomal complex: Components, Assembly and Research Methods, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005681 (spliceosomal complex) defines the dynamic ribonucleoprotein machines that catalyze pre-mRNA splicing, including the spliceosome and its assembly intermediates.
• The spliceosome is built from five small nuclear ribonucleoproteins (snRNPs) U1, U2, U4, U5, and U6 plus numerous auxiliary proteins, and it undergoes ordered assembly and disassembly cycles on each substrate RNA [2, 4].
• Spliceosomal components are essential for constitutive and regulated splicing, and their disruption is linked to cancer, developmental disorders, and splicing-related diseases [1, 8].
• Core spliceosomal proteins such as SF3B1 are recurrently mutated in hematological malignancies and solid tumors, making the spliceosome a therapeutic target.
• Spliceosome research uses knockout, point-mutation, knock-in, and overexpression cell models combined with RNA-seq, proteomics, and imaging to dissect function [4, 5].
• EDITGENE provides CRISPR-based services to generate spliceosomal gene models for mechanistic and translational studies [1, 8].
Description
The spliceosomal complex (GO:0005681) is a cellular component defined as any of a series of ribonucleoprotein complexes that contain small nuclear RNAs (snRNAs) and small nuclear ribonucleoproteins (snRNPs), formed sequentially during spliceosomal splicing of one or more substrate RNAs. These complexes also contain the RNA substrates, splicing intermediates, and final RNA products, and they carry out the removal of introns and joining of exons in cis-splicing, or the joining of a spliced leader RNA to a pre-mRNA in trans-splicing [2, 4]. The spliceosome is one of the most complex molecular machines in the cell, and its assembly and catalytic cycles are tightly regulated. Researchers study GO:0005681 to understand fundamental gene expression, to identify disease mechanisms, and to develop therapeutics targeting splicing [1, 8]. Because spliceosomal components are frequently mutated in cancer and other diseases, functional models of these genes are in high demand [1, 8].
spliceosomal complex At A Glance
| GO ID | GO:0005681 |
|---|---|
| GO term | spliceosomal complex |
| Ontology | cellular_component |
| Synonym | spliceosome, spliceosome complex |
| Major function | Catalyzes pre-mRNA splicing by removing introns and joining exons through sequential assembly of snRNPs and auxiliary proteins [2, 4] |
| Composition | Contains snRNAs (U1, U2, U4, U5, U6), snRNPs, and numerous associated proteins |
| Substrate | One or more RNA substrates, including pre-mRNA, snoRNA, or spliced leader RNA |
| Products | Spliced RNA and excised intron (lariat) in cis-splicing; joined leader and pre-mRNA in trans-splicing |
| Assembly | Sequential formation of E, A, B, B*, C, and P complexes [2, 4] |
What Is GO:0005681?
GO:0005681 describes a series of ribonucleoprotein complexes that contain snRNAs and snRNPs and assemble sequentially during spliceosomal splicing of one or more substrate RNAs. These complexes include the RNA substrate(s), splicing intermediates, and final RNA products. In cis-splicing, the initial target is a single contiguous RNA transcript (e.g., mRNA or snoRNA), and the products are a spliced RNA and an excised intron, often a lariat. In trans-splicing, there are two initial substrates: the spliced leader RNA and a pre-mRNA.
Why Is spliceosomal complex Important in Cell Biology?
The spliceosomal complex is central to gene expression because it removes introns and joins exons from the majority of human pre-mRNAs, and its regulation expands proteome diversity [2, 4]. Disruption of spliceosomal components causes widespread splicing changes that contribute to cancer, neurodegeneration, and developmental disorders [1, 8]. Understanding GO:0005681 is therefore essential for basic biology and for therapeutic development targeting splicing [1, 8].
• Spliceosomal complexes are required for maturation of most human mRNAs.
• They enable alternative splicing, which generates protein diversity.
• Mutations in spliceosomal genes such as SF3B1 are recurrent in cancer.
• Spliceosome dysfunction is implicated in hematological malignancies and solid tumors.
• Spliceosomal components adjust metabolism, including carbon-nitrogen balance in plants.
• The spliceosome is a target for anticancer drugs and splicing modulators.
• Studying spliceosomal assembly informs RNA biology and ribonucleoprotein assembly.
• Spliceosomal complexes are involved in circular RNA detection and processing.
• Disassembly mechanisms are critical for recycling splicing factors.
• Evolutionary studies reveal how early spliceosomal complexes adapted to regulated splicing.
What Happens During spliceosomal complex?
Assembly of the early spliceosomal complex
In simple terms: The spliceosome starts to assemble when U1 snRNP recognizes the beginning of an intron.
The early spliceosomal complex forms when U1 snRNP binds the 5' splice site of a pre-mRNA, followed by U2 snRNP association with the branch point, creating the A complex [2, 3]. This step is regulated and evolutionarily conserved, and it determines substrate specificity. The early complex is a checkpoint for splicing fidelity.
Activation and catalytic steps
In simple terms: The spliceosome rearranges to bring the exons together and cut out the intron.
The tri-snRNP U4/U6.U5 joins the A complex to form the B complex, which undergoes rearrangements to the activated B* complex, releasing U1 and U4 [2, 4]. The C complex then catalyzes the two transesterification reactions that excise the intron as a lariat and ligate the exons. These steps require ATP and multiple protein factors.
Disassembly and recycling
In simple terms: After splicing, the spliceosome falls apart so its parts can be reused.
Following catalysis, the post-spliceosomal complex is disassembled in an ATP-dependent manner, releasing the spliced RNA and intron lariat and recycling snRNPs for new rounds of splicing. The mechanism of disassembly initiation involves specific factors and structural changes. This step is essential for maintaining splicing capacity.
Key Genes Involved in GO:0005681 spliceosomal complex
The following genes encode core spliceosomal components and regulators that are frequently studied in the context of GO:0005681.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SF3B1 | Component of U2 snRNP, involved in branch point recognition | Recurrently mutated in cancer; target for splicing modulators |
| U2AF1 | Auxiliary factor for U2 snRNP recruitment | Mutated in myelodysplastic syndromes and cancers |
| SRSF2 | Serine/arginine-rich splicing factor | Frequently mutated in hematological malignancies |
| SNRPD1 | Core component of snRNPs | Essential for spliceosome assembly |
| SNRPD2 | Core component of snRNPs | Required for snRNP biogenesis |
| SNRPD3 | Core component of snRNPs | Involved in snRNP stability |
| SNRPB | Core component of snRNPs | Essential for splicing |
| PRPF8 | Component of U5 snRNP | Mutations linked to retinitis pigmentosa |
| PRPF31 | Component of U4/U6.U5 tri-snRNP | Mutations cause retinitis pigmentosa |
| DDX46 | RNA helicase involved in splicing | Regulates spliceosome dynamics |
| DHX15 | RNA helicase involved in disassembly | Required for spliceosome recycling |
| CDK11 | Kinase that phosphorylates SF3B1 | Regulates pre-mRNA splicing |
| EFTUD2 | Component of U5 snRNP | Mutations cause mandibulofacial dysostosis |
| SNRNP200 | RNA helicase in U5 snRNP | Mutations linked to retinitis pigmentosa |
| RBM39 | Splicing factor and target of anticancer drugs | Involved in splicing regulation |
| U2SURP | U2 snRNP-associated protein | Required for efficient splicing |
| LSM2 | Component of U6 snRNP | Essential for splicing |
How Is spliceosomal complex Regulated?
Spliceosomal complex assembly and activity are regulated by phosphorylation, particularly by CDK11, which phosphorylates SF3B1 to control pre-mRNA splicing. Additional regulation occurs through ATP-dependent RNA helicases that drive rearrangements and disassembly. The early spliceosomal complex is also subject to evolutionary and physiological regulation, such as during high-light acclimation in plants where spliceosomal components adjust carbon-nitrogen balance.
spliceosomal complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SF3B1 | Myelodysplastic syndromes, leukemia, melanoma | Knock-in of hotspot mutations in cell lines |
| U2AF1 | Myelodysplastic syndromes, lung cancer | Knockout and point-mutation models |
| SRSF2 | Chronic myelomonocytic leukemia | Overexpression and knockout models |
| PRPF8 | Retinitis pigmentosa | Knock-in of patient mutations in retinal cells |
| EFTUD2 | Mandibulofacial dysostosis | Knockout and knock-in in developmental models |
Spliceosomal mutations in cancer
Mutations in spliceosomal genes such as SF3B1, U2AF1, and SRSF2 are common in myelodysplastic syndromes, leukemias, and solid tumors, leading to altered splicing patterns that promote oncogenesis [1, 8]. These mutations often affect branch point recognition and 3' splice site selection. Targeting the spliceosome with small molecules is an active therapeutic strategy.
Spliceosomopathies and neurodegeneration
Disruption of spliceosomal components causes a group of diseases known as spliceosomopathies, including retinitis pigmentosa and mandibulofacial dysostosis, which are linked to mutations in PRPF8, PRPF31, and EFTUD2. Neurodegenerative conditions may also involve splicing dysregulation. These disorders highlight the importance of spliceosome integrity in post-mitotic cells.
Spliceosome and non-canonical BAF complex
Spliceosomal disruption can affect the non-canonical BAF complex in cancer, linking splicing to chromatin remodeling. This interaction reveals broader roles for spliceosomal components beyond splicing. Understanding these connections may open new therapeutic avenues.
From spliceosomal complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a spliceosomal gene affect cell viability? | CRISPR knockout cell lines |
| How do cancer-associated mutations alter splicing? | Point-mutation knock-in models |
| What is the subcellular localization of a spliceosomal protein? | Tagged knock-in with fluorescent protein |
| Can overexpression rescue splicing defects? | Overexpression cell models |
| What are the global splicing changes upon spliceosome disruption? | RNA-seq after knockout or knockdown |
| How does a spliceosomal component interact with chromatin remodelers? | Co-immunoprecipitation and knockout models |
How to Study the spliceosomal complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global splicing changes | Knockout or knockdown of spliceosomal genes |
| Mass spectrometry | Protein composition and modifications | Purification of spliceosomal complexes |
| Fluorescence microscopy | Localization and dynamics of splicing factors | Live-cell imaging of snRNPs |
| In vitro splicing | Catalytic activity and assembly | Mechanistic studies of spliceosome |
| CLIP-seq | RNA binding sites of splicing factors | Mapping SF3B1 interactions |
| Circular RNA detection | CircRNA in spliceosomal P complex | Purified P complex analysis |
| CRISPR screening | Genes required for splicing | Functional genomics of spliceosome |
| Phosphoproteomics | Kinase-dependent phosphorylation | CDK11 regulation of SF3B1 |
RNA sequencing and splicing analysis
RNA-seq is used to detect changes in splicing patterns, including exon skipping and intron retention, upon perturbation of spliceosomal genes. It provides a global view of splicing fidelity.
Proteomics and interactomics
Mass spectrometry-based proteomics can identify spliceosomal complex components and their post-translational modifications. Affinity purification followed by mass spectrometry reveals dynamic interactions during assembly.
Imaging and live-cell tracking
Fluorescence microscopy of tagged snRNPs and splicing factors allows visualization of spliceosome assembly in living cells. Single-molecule imaging can track splicing dynamics.
In vitro splicing assays
In vitro splicing assays using nuclear extracts or purified components reconstitute spliceosome assembly and catalysis, enabling mechanistic studies. These assays can be coupled with circular RNA detection methods.
How CRISPR Can Be Used to Study GO:0005681 spliceosomal complex
Knockout
CRISPR knockout of spliceosomal genes such as SF3B1 or U2AF1 can reveal essential functions and splicing defects, but complete loss may be lethal, requiring inducible systems. Knockout models are useful for studying gene essentiality and compensatory pathways.
Point Mutation
Point mutations in spliceosomal genes, such as SF3B1 K700E, are common in cancer and can be introduced by CRISPR to model altered splicing and drug responses. These models help dissect mutation-specific phenotypes.
Knock-in
Knock-in of tags or reporter sequences allows tracking of endogenous spliceosomal proteins and their assembly dynamics. Knock-in of patient mutations can model spliceosomopathies.
Overexpression
Overexpression of splicing factors can mimic gain-of-function states observed in cancer and test rescue of splicing defects. It is also used to study dominant-negative effects.
How EDITGENE Supports spliceosomal complex Research
Researchers studying spliceosomal complex-related genes often need to determine whether a candidate gene is causally involved in splicing regulation, disease, or drug response. This requires precise genetic models that can isolate the contribution of specific mutations or expression changes.
Contact EDITGENE today to design your custom CRISPR model for spliceosomal complex research.
Frequently Asked Questions About spliceosomal complex
What is the spliceosomal complex?
The spliceosomal complex (GO:0005681) is a series of ribonucleoprotein complexes that contain snRNAs and snRNPs and assemble sequentially during splicing of substrate RNAs.
What genes are involved in the spliceosomal complex?
Key genes include SF3B1, U2AF1, SRSF2, PRPF8, PRPF31, EFTUD2, and many snRNP core proteins [2, 4, 8].
What is the function of GO:0005681?
It catalyzes pre-mRNA splicing by removing introns and joining exons, and it also processes other RNA substrates.
How is the spliceosome assembled?
It assembles sequentially through E, A, B, B*, C, and P complexes, involving U1, U2, U4, U5, and U6 snRNPs [2, 4].
What diseases are linked to spliceosomal mutations?
Mutations in spliceosomal genes are linked to cancers such as leukemia and melanoma, and to spliceosomopathies like retinitis pigmentosa [1, 4, 8].
How can I study spliceosomal complex genes with CRISPR?
You can use knockout, point-mutation, knock-in, or overexpression models, combined with RNA-seq and proteomics [2, 4].
What is the role of SF3B1 in the spliceosome?
SF3B1 is a U2 snRNP component involved in branch point recognition and is frequently mutated in cancer.
What is the difference between cis-splicing and trans-splicing in GO:0005681?
In cis-splicing, a single RNA transcript is processed; in trans-splicing, two separate RNAs, such as a spliced leader RNA and a pre-mRNA, are joined.
How is spliceosome disassembly regulated?
Disassembly is initiated by specific factors and ATP-dependent helicases, allowing recycling of snRNPs.
Why is the spliceosome a drug target?
Because cancer-associated mutations in spliceosomal genes create dependencies that can be targeted by splicing modulators.
Conclusion
The spliceosomal complex (GO:0005681) is a dynamic ribonucleoprotein machine essential for RNA splicing and gene expression. Its components are frequently mutated in cancer and other diseases, making it a key area of research [1, 8]. CRISPR-based models and multi-omics methods provide powerful tools to dissect its function and develop therapeutics [4, 8].
References
- 1. Inoue D et al.. 2019. Spliceosomal disruption of the non-canonical BAF complex in cancer.. Nature 574(7778):432-436 PMID: 31597964
- 2. Will CL et al.. 2011. Spliceosome structure and function.. Cold Spring Harb Perspect Biol 3(7) PMID: 21441581
- 3. Borao S et al.. 2021. Evolution of the Early Spliceosomal Complex-From Constitutive to Regulated Splicing.. Int J Mol Sci 22(22) PMID: 34830325
- 4. Matera AG et al.. 2014. A day in the life of the spliceosome.. Nat Rev Mol Cell Biol 15(2):108-21 PMID: 24452469
- 5. Shi S et al.. 2021. Detecting circRNA in purified spliceosomal P complex.. Methods 196:30-35 PMID: 33577981
- 6. Araguirang GE et al.. 2024. Spliceosomal complex components are critical for adjusting the C:N balance during high-light acclimation.. Plant J 119(1):153-175 PMID: 38593295
- 7. Vorländer MK et al.. 2024. Mechanism for the initiation of spliceosome disassembly.. Nature 632(8024):443-450 PMID: 38925148
- 8. Hluchý M et al.. 2022. CDK11 regulates pre-mRNA splicing by phosphorylation of SF3B1.. Nature 609(7928):829-834 PMID: 36104565
